Phase 1b/2 APVO436 bispecific anti-CD123/CD3 antibody study

This open-label, dose-finding trial evaluates APVO436 with venetoclax and azacitidine in adult patients with newly diagnosed CD123+ AML ineligible for induction therapy. Conducted across multiple U.S. centers and sponsored by Aptevo Therapeutics, the study aims to establish a safe and effective dosing regimen for this high-risk population.